Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of “Moderate Buy” by Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $91.71.

RARE has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Wedbush restated a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, Piper Sandler lowered their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a report on Monday, March 17th.

Ultragenyx Pharmaceutical Stock Up 0.5 %

RARE stock opened at $39.36 on Tuesday. The stock has a market capitalization of $3.64 billion, a P/E ratio of -6.21 and a beta of 0.67. Ultragenyx Pharmaceutical has a 52 week low of $37.02 and a 52 week high of $60.37. The firm has a 50-day simple moving average of $41.81 and a 200-day simple moving average of $47.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the completion of the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the transaction, the chief executive officer now owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,370 shares of company stock valued at $5,751,499 over the last quarter. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its holdings in Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after acquiring an additional 268 shares during the period. Van ECK Associates Corp grew its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 294 shares in the last quarter. Motley Fool Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 0.3% during the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after buying an additional 360 shares in the last quarter. Finally, BOKF NA increased its stake in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 382 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.